KRAS and neoplasm: In addition, in KRAS-mutant lung adenocarcinoma, STK11/LKB1 inactivation induced immunosuppressive TME and innate resistance to PD-1 inhibitors through downregulation of PD-L1 in tumor cells and effector T-cell exclusion [44].